Regenerative Medicine Active on Japan MHLW Decision (CYTX) (CUR) (NBS)
Tweet
Share
E-mailGet Alerts CYTX Hot Sheet
Join SI Premium – FREE
Companies competing in the regenerative medicine category are up today following recent legislation passed in Japan.
Earlier, Cytori Therapeutics (Nasdaq: CYTX) noted,
Active today are names like: NeoStem, Inc. (Nasdaq: NBS), Neuralstem, Inc. (AMEX: CUR), Smith & Nephew (NYSE: SNN) and Cytori.
Earlier, Cytori Therapeutics (Nasdaq: CYTX) noted,
that on November 20, 2013, the Japanese legislature (Diet) approved new legislation targeted at regenerative medicine therapies. The Regenerative Medicine Law directs the Ministry of Health, Labour and Welfare (MHLW) to adopt new procedures and rules that would accelerate the clinical development of regenerative medicine and cell therapies. The Japanese Pharmaceutical Affairs Law (J-PAL) will now become the Pharmaceuticals and Medical Devices Act that will include a new branch for Regenerative Medicine Products. Regenerative Medicine Products will be regulated on a Fast Track process that focuses primarily on product safety.
Active today are names like: NeoStem, Inc. (Nasdaq: NBS), Neuralstem, Inc. (AMEX: CUR), Smith & Nephew (NYSE: SNN) and Cytori.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- Tesla (TSLA) soars on Q1 print
- Unilever (UL) shares jump as sales growth accelerate in Q1
Create E-mail Alert Related Categories
FDA, Insiders' Blog, Momentum MoversSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
